Clinical Usefulness of Urinary CrossLaps as a Sensitive Marker of Bone Metabolism.

Nakayama, Hirofumi; Yano, Tetsu; Sagara, Yoko; Ando, Kiyoshi; Kasai, Yasuyo; Taketani, Yuji

doi:10.1507/endocrj.44.479

Cited by 10 publications

(3 citation statements)

References 24 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanisms underlying such marginal unexpected effects of GnRH analogues remain unclear at present. It has been well known that bone loss caused by GnRHa treatment is associated with an increased bone turnover in women (Raven et al 1994, Nakayama et al 1997 and rats (Kurabayashi et al 1993). In our study, serum OE 2 levels fell to undetectable levels and BMD of the femoral bone and lumbar vertebrae decreased in GnRHa-treated rats.…”

Section: Discussionsupporting

confidence: 43%

Comparison of the effects of add-back therapy with various natural oestrogens on bone metabolism in rats administered a long-acting gonadotrophin-releasing hormone agonist

Wang

Yano²,

Kikuchi³

et al. 2000

Journal of Endocrinology

View full text Add to dashboard Cite

The hypoestrogenic state induced by gonadotrophinreleasing hormone agonist (GnRHa) has been shown to be effective in the treatment of oestrogen-dependent disorders but to induce bone loss. Adding back low doses of oestrogen in GnRHa therapy has been proposed to prevent bone loss. The purpose of this study is to assess the efficacy of add-back therapy with different natural oestrogens such as oestrone (OE 1 ), oestradiol (OE 2 ) and oestriol (OE 3 ). Three-month-old female rats (250 g) were subcutaneously administered microcapsules of leuprorelin acetate in doses of 1 mg/kg of body weight every 4 weeks. GnRHa therapy lasted 16 weeks, and pellets of OE 1 , OE 2 or OE 3 (0·5 mg/pellet, 60 day release), as an add-back agent, were implanted at 8 weeks of treatment. At the end of treatment, GnRHa alone decreased bone mineral density of the femur and lumbar vertebrae, and increased serum levels of bone metabolic markers such as alkaline phosphatase and osteocalcin levels. As for cancellous bone histomorphometry, GnRHa decreased bone volume while it increased osteoid volume, osteoid surface, eroded surface, mineral apposition rate and bone formation rate. All the oestrogens tested prevented these changes caused by GnRHa therapy. GnRHa induced a significant increase in body weight and a marked reduction in uterine weight, which was not observed in OE 1 or OE 2 add-back group. Body weight and uterine weight of the OE 3 add-back group were the same as those of the GnRHa group. These findings indicate that GnRHa induces high turnover bone loss which can be prevented by concomitant administration of natural oestrogens such as OE 1 , OE 2 and OE 3 to the same extent. In addition, OE 3 is unique in that it is much less effective than OE 1 and OE 2 in blocking body weight gain and in promoting growth of uterine tissues. Because of its tissue-selective actions, OE 3 could be considered as one of the most appropriate oestrogens used for GnRHa add-back therapy.

show abstract

Section: Discussionsupporting

confidence: 43%

Comparison of the effects of add-back therapy with various natural oestrogens on bone metabolism in rats administered a long-acting gonadotrophin-releasing hormone agonist

Wang

Yano²,

Kikuchi³

et al. 2000

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Because of new methods to measure activity of the bone specific isoform of AP in the daily routine, a number of studies have employed these techniques to assess the question of bone turnover in metabolic and malignant skeletal diseases [6,32,35,44]. Recently, serial measurements of BAP activity after fracture have been reported [7,8,32].…”

Section: Discussionmentioning

confidence: 99%

Sequential Changes and Pattern of Bone-Specific Alkaline Phosphatase after Trauma

Laurer¹,

Hagenbourger²,

Quast

et al. 2000

Eur J Trauma

View full text Add to dashboard Cite

Serum activity of bone specific alkaline phosphatase, a product of differentiated osteoblasts, is thought to mirror fracture healing. The precise time course after various conditions involving bone healing is, however, poorly described. The aim of our study was to evaluate sequential changes of bone alkaline phosphatase over a period of 20 weeks in traumatized patients with and without bone injuries. The bone isoenzyme of alkaline phosphatase was determined in frozen serum samples using a new automated procedure based on the wheat germ lectin precipitation method. Patients were stratified into different groups: 1.

show abstract

“…The alkaline phosphatase is synthesized in the liver and osteoblasts, and has been used as a specific marker for the liver and the bone, respectively. B-ALP mainly concentrates at the ossification sites and is involved in bone formation [15]. It has become one of the best markers for the evaluation of bone formation and bone turnover [16,17].…”

Section: Discussionmentioning

confidence: 99%

Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors

et al. 2011

View full text Add to dashboard Cite

SummaryBackgroundStudies show markers of bone turnover can help the clinician in the diagnosis and follow-up of bone metastases. The present study aimed to investigate the value of biochemical markers of bone turnover in the diagnosis and prognosis of bone metastases of malignant tumors.Material/MethodsThe serum levels of C-Telopeptide-Cross-Linked Type I Collagen (CTx), Procollagen Type I N-Terminal Propeptide (PINP), Bone-Specific Alkaline Phosphatase (B-ALP) and Osteocalcin (OST) in patients with bone metastases and control subjects were measured using radioimmunoassay and immunochemiluminescent assay.ResultsThe levels of CTx, PINP, B-ALP and OST in the metastasis group were significantly higher than those in both control groups and correlated with the number of bone metastatic sites. The levels of these markers were higher in prostate cancer patients with bone metastasis. The CTX of >426 ng/ml had the highest sensitivity and NPV, and PINP of >51.21 ng/ml had the highest specificity and PPV in healthy subjects. In addition, CTX of >547 ng/ml had the highest sensitivity and OST of >20.34 ng/ml the highest specificity in the non-metastasis group. Furthermore, both B-ALP of >15.55 ng/ml had relatively high negative predictive value and positive predictive value.ConclusionsBiochemical markers of bone turnover, including CTx, PINP, B-ALP and OST, play important roles in the diagnosis and prognosis of metastatic bone cancer. CTX had a high sensitivity, and PINP had a high specificity in predicting bone metastasis. B-ALP is an ideal biochemical marker of bone turnover for metastatic bone cancer.

show abstract

Clinical Usefulness of Urinary CrossLaps as a Sensitive Marker of Bone Metabolism.

Cited by 10 publications

References 24 publications

Comparison of the effects of add-back therapy with various natural oestrogens on bone metabolism in rats administered a long-acting gonadotrophin-releasing hormone agonist

Comparison of the effects of add-back therapy with various natural oestrogens on bone metabolism in rats administered a long-acting gonadotrophin-releasing hormone agonist

Sequential Changes and Pattern of Bone-Specific Alkaline Phosphatase after Trauma

Value of C-telopeptide-cross-linked Type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen Type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors

Contact Info

Product

Resources

About